Gauss-2, Rutherford-2, Laplace-2, Descartes, And Tesla part B: PCSK9 inhibitors gain momentum

Global Cardiology Science and Practice

Volumn 2014, Issue 4, 2014, Pages

  Hassan, Mohamed ^a,b   Yacoub, Magdi ^c  

^a Magdi Yacoub Heart Founda tion   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c QATAR CARDIOVASCULAR RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EVOLOCUMAB; EZETIMIBE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; ROSUVASTATIN; SERINE PROTEINASE; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL EFFECTIVENESS; CLINICAL STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLUENZA; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCLE DISEASE; MUSCLE SPASM; MYALGIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; STRUCTURE ANALYSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84948466608     PISSN: None     EISSN: 23057823     Source Type: Journal    
DOI: 10.5339/gcsp.2014.49     Document Type: Article

References (21)

1. Baigent C, Blackwell L, Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-81.
2. Stone NJ, Robinson FJ, H F.A., et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J. Am. Coll. Cardiol. 2014; 63(25-PA):2889-2934.
3. Catapano AL, Chairperson EAS, Ireland IG, et al. ESC / EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011; 32:1769-1818.
4. Anderson TJ, Grégoire J, Hegele R.A., et al. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can. J. Cardiol. 2013; 29:151-167.
5. Zhang H, Plutzky J, Skentzos S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann. Intern. Med. 2013; 158(7):526-34.
6. Lambert G, Sjouke B, Choque B., Kastelein JJP, Hovingh GK. The PCSK9 decade. J. Lipid Res. 2012; 53(12):2515-24.
7. Elguindy A, Yacoub MH. The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research. Glob. Cardiol. Sci. Pract. 2013; 4:1-5.
8. Piper DE, Jackson S, Liu Q., et al. Article The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol. Structure 2007; 15:545-552.
9. Giugliano RP et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type9 incombination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI57): a randomised, placebo-controlled, doseranging, phase2 study. Lancet 2012; 380:2007-2017.
10. Raal F et al. Low-density lipoprotein cholesterol-lowering effects of AMG145, a monoclonal antibody to proprotein convertase subtilisin/ kexin type9 serine protease in patients with heterozygous familial hypercholesterolemia: theReduction of LDL-C with PCSK9 Inhibi. Circulation 2012; 126:2408-2417.
11. Sullivan D et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308:2497-2506.
12. Koren MJ, Giugliano RP, Raal F.J., et al. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial. Circulation 2013; 129(2):234-43.
13. Urban D, Poss J, Böhm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J. Am. Coll. Cardiol. 2013; 62(16):1401-8.
14. Stroes E, Colquhoun D, Sullivan D., et al. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. J Am Coll Cardiol 2014; 63(23):2541-8.
15. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2014; October. doi:10.1016/S0140-6736(14)61399-4.
16. Raal FJ, Honarpour N, Blom D.J., et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2014; October. doi:10.1016/S0140-6736(14)61374-X.
17. Robinson JG, Nedergaard BS, Rogers W.J., et al. Effect of Evolocumab or Ezetimibe Added to Moderateor High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial. JAMA 2014; 311(18):1870-1882.
18. Lillestol MJ, Toth PD, Burgess L, et al. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. A/EJM 2014; 370(19):1809-1819.
19. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat. Rev. Cardiol. 2014; 11(10):563-75.
20. Larosa, J. C, Pedersen, T. R., Somaratne R, & Wasserman SM. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. Am. J. Cardiol. 2013; 111:1221-1229.
21. Martin SS et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J. Am. Coll. Cardiol. 2013; 62:732-739.